PF 3644022

PF 3644022 Suppliers list
Company Name: J & K SCIENTIFIC LTD.  
Tel: 18210857532 18210857532
Email: jkinfo@jkchemical.com
Company Name: Chemsky (shanghai) International Co.,Ltd  
Tel: 021-50135380
Email: shchemsky@sina.com
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Wuhan TCASChem Technology Co., Ltd.  
Tel: 027-86697669 13986148687
Email: sales@tcaschem.com
Company Name: Sichuan Wei Keqi Biological Technology Co., Ltd.  
Tel: 028-81700200 18116577057
Email: 3003855609@qq.com

PF 3644022 manufacturers

  • PF-3644022
  • PF-3644022 pictures
  • $31.00
  • 2026-07-27
  • CAS:1276121-88-0
  • Purity: 99.12%
  • Supply Ability: 10g
PF 3644022 Basic information
Product Name:PF 3644022
Synonyms:PF 3644022;(10R)-9,10,11,12-Tetrahydro-10-Methyl-3-(6-Methyl-3-pyridinyl)-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one;MK2 INHIBITOR;8H-[1,4]Diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one, 9,10,11,12-tetrahydro-10-methyl-3-(6-methyl-3-pyridinyl)-, (10R)-;(R)-10-Methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one;MAPKAP kinase 2,monocytic,lipopolysaccharide,IL-6,TNFα,safety,Anti-inflammatory,PF3644022,orally,PRAK,efficacious,inhibit,PF-3644022,Mitogen-activated protein kinase activated protein kinase 2,p38 MAPK,Inhibitor,MK3,MAP kinase activated protein kinase 2,MAPKAPK2 (MK2),MAPK activated protein kinase 2,PF 3644022;PF-3644022, 10 mM in DMSO
CAS:1276121-88-0
MF:C21H18N4OS
MW:374.46
EINECS:
Product Categories:Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:1276121-88-0.mol
PF 3644022 Structure
PF 3644022 Chemical Properties
Melting point >180°C (dec.)
Boiling point 703.3±60.0 °C(Predicted)
density 1.298±0.06 g/cm3(Predicted)
storage temp. 2-8°C(protect from light)
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
pka13.51±0.40(Predicted)
color Off-White to Yellow
Safety Information
HS Code 2934999090
MSDS Information
PF 3644022 Usage And Synthesis
UsesPF-3644022 is a potent freely reversible ATP-competitive compound that inhibits MK2 activity (Ki = 3 nM) with good selectivity when profiled against 200 human kinases. PF-3644022 is a benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor α production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
Biological Activitypf-3644022 is a potent and selective mitogen-activated protein kinase (mapk)-activated protein kinase-2 (mk2) inhibitor (ki =3 nm). [1]pf-3644022 is the first oral mk2 inhibitor in both acute and chronic models of inflammation. pf-3644022 reversibly atp-competitive inhibits mk2 enzyme activity with good selectivity across 200 human kinases. [1]in the human u937 monocytic cell line or peripheral blood mononuclear cells, pf-3644022 potently inhibits tnf production with ic50 value of 160 nm. in lps-stimulated human whole blood, pf-3644022 blocks tnf and il-6 production with ic50 values of 1.6 and 10.3 μm, respectively. in u937 cells and blood, inhibition of tnf correlates closely with inhibition of phospho-heat shock protein 27, a target biomarker of mk2 activity. [1]in the rat lps-induced tnf model, pf-3644022 efficacy in the chronic inflammation model is strongly correlated with maintaining a cmin higher than the ec50 measured. pf-3644022 exhibits efficaciously oral activity and good pharmacokinetic parameters in both the chronic streptococcal cell wall-induced arthritis model and the rat acute lps-induced tnf model. [1]
in vivo

PF-3644022 (3-100 mg/kg; oral gavage; twice a day; for 12 days; Lewis rats) treatment shows dose-dependent inhibition of chronic paw swelling measured on day 21 after 12 days of oral dosing, with ED50 value of 20 mg/kg[1].

Animal Model:Female Lewis rats (125-140 g) injected with streptococcal cell wall[1]
Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg
Administration:Oral gavage; twice a day; for 12 days
Result:Showed dose-dependent inhibition of chronic paw swelling measured on day 21 after 12 days of oral dosing.
storageStore at +4°C
references1. mourey rj, burnette bl, brustkern sj et al. a benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. j pharmacol exp ther. 2010 jun;333(3):797-807. doi: 10.1124/jpet.110.166173. epub 2010 mar 17.
PF 3644022 Preparation Products And Raw materials
Tag:PF 3644022(1276121-88-0) Related Product Information
PF-04995274 brepocitinib Nirogacestat PF-06650833 PF-05089771 (tosylate) PF-06424439 PF-06447475 PF 573228 PF-06882961 PF-5190457 PF-05212384 [(3R)-1-[2-[1-(4-Chloro-1H-pyrazol-1-yl)cyclopropyl]-3H-imidazo[4,5-b]pyridin-5-yl]-3-piperidinyl]-1-pyrrolidinyl-methanone methanesulfonate PF-04691502 1H-Indole-2-carboxamide, 4-methoxy-N-[(1S)-3-methyl-1-[[[(1S)-2-oxo-1-[[(3S)-2-oxo-3-pyrrolidinyl]methyl]-3-(phosphonooxy)propyl]amino]carbonyl]butyl]- PF 477736